Does AVXL pay dividends?

Anavex Life Sciences Corp (AVXL) does not currently pay a regular dividend.

What is AVXL's market cap?

Anavex Life Sciences Corp (AVXL) has a market capitalization of $259.55M with a current stock price of $2.80.

Anavex Life Sciences Corp (AVXL)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$2.80

-0.19 (-6.35%)

Market Cap: $259.55M

Last updated: Sep 01, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

74%(29/39)

Avg Surprise

+12.88%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.07

Range$-0.07 - $-0.07

1 analysts

Revenue Consensus

Range$0 - $0

1 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.12

Range$-0.12 - $-0.12

1 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate Drift

90d ago$0.00+100.0%

60d ago$0.00+100.0%

30d ago$-0.12+0.0%

7d ago$-0.12+0.0%

Current$-0.12

Revenue Consensus

Range$0 - $0

0 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.12	$-0.12 - $-0.12	-	-	1	No revisions (30d)	-
Sep 30, 2026Sep 26EST	-	$-0.07	$-0.07 - $-0.07	-	-	1	-	-
Jun 30, 2026Jun 26 Reported Jul 30, 2026Reported Jul 30	$0.08	$-0.08	$-0.08 - $-0.08	+200.00%	Beat	1	2 0 30d	+150.0%
Mar 31, 2026Mar 26 Reported Jun 23, 2026Reported Jun 23	$-0.13	$-0.07	$-0.07 - $-0.07	-85.71%	Miss	1	2 0 30d	+0.0%
Dec 31, 2025Dec 25 Reported Feb 9, 2026Reported Feb 9	$-0.06	$-0.11	$-0.12 - $-0.10	+45.45%	Beat	2	1 0 30d	+57.1%
Sep 30, 2025Sep 25 Reported Nov 25, 2025Reported Nov 25	$-0.11	$-0.14	$-0.16 - $-0.13	+22.86%	Beat	3	1 1 30d	+21.4%
Jun 30, 2025Jun 25 Reported Aug 12, 2025Reported Aug 12	$-0.16	$-0.14	$-0.16 - $-0.13	-14.29%	Miss	2	1 0 30d	-14.3%
Mar 31, 2025Mar 25 Reported May 13, 2025Reported May 13	$-0.13	$-0.15	$-0.16 - $-0.14	+13.33%	Beat	2	1 0 30d	+0.0%
Dec 31, 2024Dec 24 Reported Feb 12, 2025Reported Feb 12	$-0.14	$-0.17	$-0.17 - $-0.17	+17.65%	Beat	1	1 0 30d	-27.3%
Sep 30, 2024Sep 24 Reported Dec 23, 2024Reported Dec 23	$-0.14	$-0.17	$-0.17 - $-0.17	+17.65%	Beat	2	1 0 30d	-16.7%
Jun 30, 2024Jun 24 Reported Aug 6, 2024Reported Aug 6	$-0.14	$-0.18	$-0.21 - $-0.12	+22.22%	Beat	3	No revisions (30d)	+0.0%
Mar 31, 2024Mar 24 Reported May 9, 2024Reported May 9	$-0.13	$-0.13	$-0.13 - $-0.09	+0.00%	Beat	2	No revisions (30d)	+23.5%
Dec 31, 2023Dec 23 Reported Feb 7, 2024Reported Feb 7	$-0.11	$-0.15	$-0.15 - $-0.14	+26.67%	Beat	2	No revisions (30d)	+35.3%
Sep 30, 2023Sep 23 Reported Nov 27, 2023Reported Nov 27	$-0.12	$-0.15	$-0.16 - $-0.13	+20.00%	Beat	3	No revisions (30d)	+33.3%
Jun 30, 2023Jun 23 Reported Aug 8, 2023Reported Aug 8	$-0.14	$-0.17	$-0.17 - $-0.16	+17.65%	Beat	3	No revisions (30d)	+12.5%
Mar 31, 2023Mar 23 Reported May 9, 2023Reported May 9	$-0.17	$-0.18	$-0.20 - $-0.18	+5.56%	Beat	3	No revisions (30d)	-21.4%
Dec 31, 2022Dec 22 Reported Feb 7, 2023Reported Feb 7	$-0.17	$-0.19	$-0.20 - $-0.18	+10.53%	Beat	3	No revisions (30d)	-21.4%
Sep 30, 2022Sep 22 Reported Nov 28, 2022Reported Nov 28	$-0.18	$-0.16	$-0.17 - $-0.15	-12.50%	Miss	5	No revisions (30d)	-20.0%
Jun 30, 2022Jun 22 Reported Aug 9, 2022Reported Aug 9	$-0.16	$-0.16	$-0.16 - $-0.16	+0.00%	Beat	0	No revisions (30d)	-14.3%
Mar 31, 2022Mar 22 Reported May 10, 2022Reported May 10	$-0.14	$-0.17	$-0.18 - $-0.16	+17.65%	Beat	4	No revisions (30d)	-16.7%
Dec 31, 2021Dec 21 Reported Feb 9, 2022Reported Feb 9	$-0.14	$-0.16	$-0.16 - $-0.14	+12.50%	Beat	4	No revisions (30d)	-16.7%
Sep 30, 2021Sep 21 Reported Nov 24, 2021Reported Nov 24	$-0.15	$-0.14	$-0.17 - $-0.13	-7.14%	Miss	4	No revisions (30d)	-50.0%
Jun 30, 2021Jun 21 Reported Aug 12, 2021Reported Aug 12	$-0.14	$-0.14	$-0.15 - $-0.12	+0.00%	Beat	5	No revisions (30d)	-27.3%
Mar 31, 2021Mar 21 Reported May 13, 2021Reported May 13	$-0.12	$-0.15	$-0.15 - $-0.12	+20.00%	Beat	4	No revisions (30d)	+0.0%
Dec 31, 2020Dec 20 Reported Feb 11, 2021Reported Feb 11	$-0.12	$-0.12	$-0.12 - $-0.12	+0.00%	Beat	2	No revisions (30d)	+0.0%
Sep 30, 2020Sep 20 Reported Dec 28, 2020Reported Dec 28	$-0.10	$-0.13	$-0.14 - $-0.12	+23.08%	Beat	4	No revisions (30d)	-42.9%
Jun 30, 2020Jun 20 Reported Aug 6, 2020Reported Aug 6	$-0.11	$-0.13	$-0.14 - $-0.13	+15.38%	Beat	4	No revisions (30d)	+21.4%
Mar 31, 2020Mar 20 Reported May 7, 2020Reported May 7	$-0.12	$-0.16	$-0.20 - $-0.13	+25.00%	Beat	4	No revisions (30d)	+29.4%
Dec 31, 2019Dec 19 Reported Feb 6, 2020Reported Feb 6	$-0.12	$-0.12	$-0.16 - $-0.12	+0.00%	Beat	2	No revisions (30d)	+25.0%
Sep 30, 2019Sep 19 Reported Dec 16, 2019Reported Dec 16	$-0.07	N/A	-	+53.33%	Beat	2	No revisions (30d)	+46.2%
Jun 30, 2019Jun 19 Reported Aug 7, 2019Reported Aug 7	$-0.14	$-0.17	$-0.18 - $-0.16	+17.65%	Beat	2	No revisions (30d)	-133.3%
Mar 31, 2019Mar 19 Reported May 8, 2019Reported May 8	$-0.17	$-0.14	$-0.14 - $-0.14	-21.43%	Miss	1	No revisions (30d)	-54.5%
Dec 31, 2018Dec 18 Reported Feb 7, 2019Reported Feb 7	$-0.16	$-0.13	$-0.13 - $-0.13	-23.08%	Miss	1	No revisions (30d)	-77.8%
Sep 30, 2018Sep 18 Reported Dec 12, 2018Reported Dec 12	$-0.13	$-0.11	$-0.11 - $-0.11	-18.18%	Miss	0	No revisions (30d)	-8.3%
Jun 30, 2018Jun 18 Reported Aug 9, 2018Reported Aug 9	$-0.06	$-0.10	$-0.12 - $-0.09	+40.00%	Beat	3	No revisions (30d)	+33.3%
Mar 31, 2018Mar 18 Reported May 10, 2018Reported May 10	$-0.11	$-0.10	$-0.10 - $-0.10	-10.00%	Miss	2	No revisions (30d)	-175.0%
Dec 31, 2017Dec 17 Reported Feb 7, 2018Reported Feb 7	$-0.09	$-0.08	$-0.08 - $-0.08	-12.50%	Miss	0	No revisions (30d)	-12.5%
Sep 30, 2017Sep 17 Reported Dec 11, 2017Reported Dec 11	$-0.12	$-0.10	$-0.10 - $-0.10	-20.00%	Miss	2	No revisions (30d)	+33.3%
Jun 30, 2017Jun 17 Reported Aug 7, 2017Reported Aug 7	$-0.09	$-0.09	$-0.09 - $-0.09	+0.00%	Beat	1	No revisions (30d)	-
Mar 31, 2017Mar 17 Reported May 10, 2017Reported May 10	$-0.04	N/A	-	+55.56%	Beat	-	-	-
Dec 31, 2016Dec 16 Reported Feb 7, 2017Reported Feb 7	$-0.08	$-0.11	-	+27.27%	Beat	-	-	-
Sep 30, 2016Sep 16 Reported Dec 12, 2016Reported Dec 12	$-0.18	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-12.73	EV/EBITDA	-5.54x
Price/FCF	-7.95x	FCF Yield	-12.58%
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-12.80%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	4.14x
Current Ratio	15.62x	Quick Ratio	15.62x
Trading Statistics
Beta	1.14	Avg Volume	917.47K
52-Week High	$10.40	52-Week Low	$2.25

Technical Indicators Dashboard

Moving Averages

SMA 10$3.18

SMA 20$3.24

SMA 50$2.83

SMA 200$3.53

EMA 10$3.12

EMA 20$3.11

EMA 50$2.99

EMA 200$4.00

MACD

Line: 0.06Signal: 0.13Hist: -0.07

ADX

ADX: 25.3+DI: 27.6-DI: 30.7

Aroon & PSAR

Aroon Up84.0

Aroon DownN/A

PSAR$3.67

Bollinger Bands

Upper Band$3.59

Lower Band$2.89

%B Position2142%(Upper)

Band Width-0.13

RSI (14-Day)

Neutral

42.9

Momentum Oscillators

Stoch %K4.4

Stoch %D17.9

Williams %R-97.8

ROC (10d)-12.8%

Momentum-0.41

CCI (20d)-221.3

MFI (14d)33.4

Volatility Measures

ATR (14d)$0.20(7.2%)

StdDev (20d)0.17

Hist Vol88.1%(High)

Volume Flow

VWAP$2.85

OBV-50.0M

AD Line-19.9M

CMF (20d)-0.093

Volume Metrics

Avg Vol (20d)891.1K

Vol Ratio1.2x

VWMA (20d)$3.26

Pivot Points

R3$3.26

R2$3.20

R1$3.09

Pivot Point$3.03

S1$2.92

S2$2.86

S3$2.75

Advanced Oscillators

TSI7.50

Ultimate Osc40.6

KST189.77

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Cost of Revenue	$0	$0	$0	N/A	$0	$0	$0	N/A	$0	$0	$0	N/A
Gross Profit	$0	$0	$0	N/A	$0	$0	$0	N/A	$0	$0	$0	N/A

Operating Expenses	$-6,737,000	$6.48M	$6.78M	$10.84M	$14.46M	$12.51M	$13.59M	$14.27M	$14.60M	$12.62M	$11.38M	$12.66M
R&D	$-4,705,000	$4.19M	$4.66M	$7.29M	$9.96M	$9.89M	$10.45M	$11.61M	$11.81M	$9.73M	$8.68M	$10.06M
SG&A	$-2,032,000	$2.29M	$2.13M	$3.55M	$4.50M	$2.62M	$3.15M	$2.66M	$2.79M	$2.90M	$2.69M	$2.60M
Operating Income	$6.74M	$-6,484,000	$-6,782,000	$-10,844,000	$-14,459,000	$-12,513,000	$-13,592,000	$-14,272,000	$-14,603,000	$-12,624,000	$-11,378,000	$-12,658,000

Interest Income	$0	$27,000	$33,000	$13,000	$0	$96,000	$412,000	$701,000	$526,000	$472,000	$592,000	$670,000
Interest Expense	$-1,072,000	$-1,061,000	$-1,079,000	$-999,000	$-1,075,000	$-1,210,000	$-1,394,000	$-1,760,000	$-1,796,000	$-1,756,000	$-2,008,000	$-1,958,000
Income Before Tax	$7.82M	$-5,338,000	$-5,663,000	$-9,827,000	$-13,243,000	$-11,196,000	$-12,111,000	$-11,620,000	$-12,214,000	$-10,546,000	$-8,622,000	$-10,217,000
Income Tax Expense	$0	$0	$18,000	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$7.82M	$-5,338,000	$-5,681,000	$-9,827,000	$-13,243,000	$-11,196,000	$-12,111,000	$-11,620,000	$-12,214,000	$-10,546,000	$-8,622,000	$-10,146,000

EBITDA	$6.75M	$-6,426,000	$-6,775,000	$-10,966,000	$-14,318,000	$-12,502,000	$-13,917,000	$-14,081,000	$-14,536,000	$-12,774,000	$-11,222,000	$-12,845,000
EBIT	$6.75M	$-6,426,000	$-6,775,000	$-10,966,000	$-14,318,000	$-12,502,000	$-13,917,000	$-14,081,000	$-14,536,000	$-12,774,000	$-11,222,000	$-12,845,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about AVXL

News

Anavex Life Sciences Releases Q3 2026 Financial Results

Anavex Life Sciences Corp. reported a significant turnaround in its Q3 2026 financial results, achieving diluted earnings of $0.08 per share and a net income of $7.8M. This marks a 150.0% increase from a loss in the previous year, driven by the advancement of its precision medicine pipeline for central nervous system disorders. Wall Street analysts maintain a positive outlook, with a consensus of four buy ratings and one hold.

AlphaStreet•Aug 25, 2026 3:13 PM8/25/26•

Bullish

Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update

Anavex Life Sciences reported its third fiscal quarter 2026 financial results, highlighting significant regulatory progress across its Alzheimer’s disease, Rett syndrome, and Fragile X syndrome programs. The company submitted all Alzheimer's clinical study data to the FDA, requested a meeting to discuss adding pediatric patients to its Rett syndrome Phase 3 study, and plans an IND submission for Fragile X syndrome in September. Anavex also reported a net income of $7.8 million for the quarter, largely due to a reversal of stock-based compensation expenses.

Anavex Life Sciences•Aug 25, 2026 12:26 PM8/25/26•

Bullish

Anavex Life Sciences reports Q3 FY2026 net income $7.8M, cash $118.3M

Anavex Life Sciences reported a net income of $7.8 million, or $0.08 per share, for Q3 FY2026, a turnaround from a previous year's loss. The company holds $118.3 million in cash, expected to fund operations into mid to late fiscal 2028. Anavex also provided updates on its Alzheimer’s, Rett syndrome, and Fragile X syndrome programs, including plans for discussions with the FDA for a Phase 3 Alzheimer's protocol.

TradingView•Aug 25, 2026 12:13 PM8/25/26•

Bullish

PVG mounts six-seat board challenge at Anavex (AVXL)

PVG Asset Management Corporation has launched a proxy contest against Anavex Life Sciences (AVXL), filing an amended preliminary proxy statement to solicit votes for its slate of six director nominees at the 2026 annual meeting. PVG and associated participants collectively own 0.36% of Anavex's outstanding shares. The filing includes a script from a PVG YouTube video that discusses broader market conditions alongside PVG's frustration with Anavex's management, including missed earnings reports and recent executive changes, advocating for a new board to ensure the company's drug pipeline progresses.

Stock Titan•Aug 20, 2026 9:41 AM8/20/26•

Bearish

Form 8K Anavex Life Sciences Corp For: 17 August By Investing.com

This article reports on the filing of a Form 8K by Anavex Life Sciences Corp. on August 17th. The brief notice from Investing.com provides the filing date and company name without further details.

Investing.com UK•Aug 17, 2026 1:24 PM8/17/26•

Neutral

Frequently Asked Questions About AVXL

Does AVXL pay dividends?: Anavex Life Sciences Corp (AVXL) does not currently pay a regular dividend.
What is AVXL's market cap?: Anavex Life Sciences Corp (AVXL) has a market capitalization of $259.55M with a current stock price of $2.80.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In